CN112920131A - 一类1,2,4-三氮唑衍生物及其制法和用途 - Google Patents
一类1,2,4-三氮唑衍生物及其制法和用途 Download PDFInfo
- Publication number
- CN112920131A CN112920131A CN202110233174.2A CN202110233174A CN112920131A CN 112920131 A CN112920131 A CN 112920131A CN 202110233174 A CN202110233174 A CN 202110233174A CN 112920131 A CN112920131 A CN 112920131A
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- compounds
- cancer
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Description
待测化合物 | IC<sub>50</sub>(μM/L) | 待测化合物 | IC<sub>50</sub>(μM/L) |
实施例2化合物 | 49.02 | 实施例51化合物 | 43.34 |
实施例9化合物 | 22.36 | 实施例52化合物 | 17.11 |
实施例13化合物 | 18.01 | 实施例55化合物 | 16.14 |
实施例15化合物 | 48.04 | 实施例56化合物 | 45.32 |
实施例17化合物 | 14.37 | 实施例57化合物 | 5.29 |
实施例19化合物 | 83.13 | 实施例64化合物 | 4.87 |
实施例24化合物 | 10.66 | 实施例65化合物 | 13.41 |
实施例25化合物 | 60.35 | 实施例66化合物 | 40.67 |
实施例36化合物 | 44.45 | 实施例68化合物 | 45.18 |
实施例38化合物 | 50.38 | 实施例69化合物 | 40.67 |
实施例39化合物 | 54.81 | 实施例71化合物 | 44.23 |
实施例40化合物 | 12.01 | 实施例73化合物 | 13.32 |
实施例44化合物 | 15.90 | 实施例74化合物 | 13.04 |
实施例45化合物 | 67.44 | 实施例76化合物 | 8.25 |
实施例46化合物 | 36.71 | 实施例78化合物 | 8.35 |
实施例48化合物 | 37.35 | 实施例80化合物 | 94.47 |
实施例49化合物 | 13.17 | 实施例82化合物 | 35.71 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110233174.2A CN112920131A (zh) | 2021-03-03 | 2021-03-03 | 一类1,2,4-三氮唑衍生物及其制法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110233174.2A CN112920131A (zh) | 2021-03-03 | 2021-03-03 | 一类1,2,4-三氮唑衍生物及其制法和用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112920131A true CN112920131A (zh) | 2021-06-08 |
Family
ID=76173107
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110233174.2A Pending CN112920131A (zh) | 2021-03-03 | 2021-03-03 | 一类1,2,4-三氮唑衍生物及其制法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112920131A (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114957162A (zh) * | 2022-06-30 | 2022-08-30 | 潍坊医学院附属医院 | 一类噻二唑母核类化合物的制备与应用 |
WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
WO2022235870A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
WO2022235864A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112174903A (zh) * | 2019-07-01 | 2021-01-05 | 清华大学 | Tlr8的小分子调节剂 |
-
2021
- 2021-03-03 CN CN202110233174.2A patent/CN112920131A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112174903A (zh) * | 2019-07-01 | 2021-01-05 | 清华大学 | Tlr8的小分子调节剂 |
Non-Patent Citations (1)
Title |
---|
孔娇: ""蛋白酪氨酸磷酸酶SHP2 及其抑制剂的研究进展"", 《药学进展》 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
WO2022235870A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
WO2022235864A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
CN114957162A (zh) * | 2022-06-30 | 2022-08-30 | 潍坊医学院附属医院 | 一类噻二唑母核类化合物的制备与应用 |
CN114957162B (zh) * | 2022-06-30 | 2024-03-12 | 潍坊医学院附属医院 | 一类噻二唑母核类化合物的制备与应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112920131A (zh) | 一类1,2,4-三氮唑衍生物及其制法和用途 | |
CN113024508A (zh) | 一类含氮杂环衍生物及其制法和用途 | |
CN104003988A (zh) | 基于3-氨基-β-咔啉及其衍生物的CDK2激酶抑制剂及其制备方法和用途 | |
CN107383004B (zh) | 2-氨基咪唑并吡啶类衍生物及制备和应用 | |
Wang et al. | Synthesis and biological evaluation of new 4β-anilino-4′-O-demethyl-4-desoxypodophyllotoxin derivatives as potential antitumor agents | |
CN104341386A (zh) | 一类芳基杂环小分子化合物、其衍生物及其制备方法和用途 | |
CN108558865B (zh) | 一种以吡啶并[2,3-d]嘧啶结构为母核的衍生物及其制备方法和应用 | |
CN110240598B (zh) | 甲酰胺衍生物的制备方法及其中间体化合物 | |
CN111253339B (zh) | 一类姜黄素衍生物的合成制备方法以及在癌症治疗的应用 | |
CN103922992B (zh) | 一种抗癌活性吲哚酮衍生物、合成方法及其用途 | |
CN110818609A (zh) | 3-乙酰基吲哚类brpf1抑制剂的制备方法及其用途 | |
CN111454254B (zh) | 一种具有含氟取代基的苯并咪唑衍生物的制备及其应用 | |
CN111875601A (zh) | 一种吲哚嗪类化合物的合成方法及用途 | |
CN112441970A (zh) | 一类2,5-二取代-3-氨基吡啶化合物及其制法和用途 | |
Liu et al. | Synthesis and anti-tumor activity evaluation of novel 7-fluoro-4-(1-piperazinyl) quinolines | |
CN110357905B (zh) | 作为蛋白激酶抑制剂的大环类衍生物及其制备方法和用途 | |
CN111423379B (zh) | 取代3-吲唑类Mcl-1蛋白抑制剂及制备方法和应用 | |
CN113072550B (zh) | 一种高选择性成纤维细胞生长因子受体抑制剂和应用 | |
CN110526854B (zh) | 一种ɑ,β-不饱和酮衍生物、制备方法及作为药物的用途 | |
CN111057004A (zh) | 一种n-邻取代苯基苯甲酰胺-4-甲氨基吖啶类化合物及其制备方法和用途 | |
CN111333663A (zh) | 一类环烷基并噻吩并嘧啶酮化合物及其制法和用途 | |
WO2011120314A1 (zh) | 一种作为抗肿瘤药物的联苯化合物及其制备方法 | |
WO2022135412A1 (zh) | 酪蛋白激酶1ε抑制剂的晶型、制备方法及其应用 | |
CN113321651B (zh) | 吡唑并吡啶异羟肟酸类化合物、其制备方法及其应用 | |
CN114133355B (zh) | 一种2-苯基-1h-苯并咪唑类衍生物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Ma Ying Inventor after: Zhou Liang Inventor after: Wang Runling Inventor after: Cheng Xianchao Inventor after: Wu Jingwei Inventor after: Ma Yangchun Inventor after: Li Weiya Inventor after: Du Shan Inventor after: Li Lipeng Inventor after: Li Haoxin Inventor before: Ma Ying Inventor before: Wang Runling Inventor before: Wu Jingwei Inventor before: Ma Yangchun Inventor before: Li Weiya Inventor before: Du Shan Inventor before: Li Lipeng Inventor before: Li Haoxin Inventor before: Zhou Liang |
|
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210608 |